Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Mesenchymal Stem Cells and Dendritic Cells in Immune Diseases and...
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Mesenchymal Stem Cells and Dendritic Cells in Immune Diseases and Cancers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 9320

Special Issue Editor

Dr. Chi Chien Lin

E-Mail Website
Guest Editor
Institute of Biomedical Science, The iEGG and Animal Biotechnology Center, National Chung-Hsing University, Taichung 402, Taiwan
Interests: immuno-oncology; autoimmunity; bioactive natural/organic synthetic pharmaceuticals

Special Issue Information

Dear Colleagues,

In human cord blood, CD34+ hematopoietic stem cells (HSCs) are transformed into precursor dendritic cells (DCs) after the stimulation of GM-CSF and TNF-α. Generally, DCs could be activated by pattern recognition receptors, and further complete their maturation, migration to lymph nodes, and T cells’ activation. Th1, Th2, Th17, and Treg would then be stimulated by IL-12, IL-23, IL-27, and IL-10. The abovementioned process is essential in various immune responses in human bodies against various diseases and cancers. The DCs could be categorized into immunogenic DCs and tolerogenic DCs. The former are essential for cancers and infections, and the latter are important for autoimmune disorders and rejections after transplant surgeries. Recently, the number of studies regarding mesenchymal stem cells (MSCs) is blooming, and various clinical trials are being published. These multipotent cells supply us with more ammunition to cope with various diseases and cancers. Many studies have indicated that HSCs primarly reside in endothelail cells and pericytes of the vasculature, and some expansion protocols have been proposed based on this. For this relationship in distribution, some in vitro studies have indicated that MSCs could interact with various immune cells, especially DCs, to modulate immune systems. However, there are still too few studies regarding this to make conclusions.

Therefore, we sincerely welcome all scholars worldwide to discuss this interesting issue; we welcome original articles and review articles regarding the following topics:

  1. Interaction between MSCs and DCs.
  2. Cellular therapies of DCs or MSCs in treating immune-related disorders or cancers.
  3. Isolation, purification, expansion, and differentiation of MSCs or DCs.
  4. Clinical studies regarding the application of MSCs or DCs in treating cancers or immune-related disorders.

Dr. Chi Chien Lin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell communication
  • cell differentiation
  • cell movement
  • dendritic cells/immunology
  • dendritic cells/physiology
  • mesenchymal stem cells/immunology
  • mesenchymal stem cells/physiology

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 11018 KiB  
Article
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC)
by Nicoletta Cordani, Daniela Lisini, Valentina Coccè, Giuseppe Paglia, Ramona Meanti, Maria Grazia Cerrito, Pietro Tettamanti, Luca Bonaffini, Francesca Paino, Giulio Alessandri, Angela Marcianti, Aldo Giannì, Chiara Villa, Mario Mauri, Luca Mologni, Antonio Torsello, Augusto Pessina and Marina Elena Cazzaniga
Int. J. Mol. Sci. 2023, 24(6), 5864; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24065864 - 20 Mar 2023
Cited by 5 | Viewed by 1951
Abstract
Triple-negative breast cancer (TNBC) is a very aggressive disease even in its early stages and is characterized by a severe prognosis. Neoadjuvant chemotherapy is one of the milestones of treatment, and paclitaxel (PTX) is among the most active drugs used in this setting. [...] Read more.
Triple-negative breast cancer (TNBC) is a very aggressive disease even in its early stages and is characterized by a severe prognosis. Neoadjuvant chemotherapy is one of the milestones of treatment, and paclitaxel (PTX) is among the most active drugs used in this setting. However, despite its efficacy, peripheral neuropathy occurs in approximately 20–25% of cases and represents the dose-limiting toxicity of this drug. New deliverable strategies to ameliorate drug delivery and reduce side effects are keenly awaited to improve patients’ outcomes. Mesenchymal stromal cells (MSCs) have recently been demonstrated as promising drug delivery vectors for cancer treatment. The aim of the present preclinical study is to explore the possibility of a cell therapy approach based on the use of MSCs loaded with PTX to treat TNBC-affected patients. For this purpose, we in vitro evaluated the viability, migration and colony formation of two TNBC cell lines, namely, MDA-MB-231 and BT549, treated with MSC-PTX conditioned medium (MSC-CM PTX) in comparison with both CM of MSCs not loaded with PTX (CTRL) and free PTX. We observed stronger inhibitory effects on survival, migration and tumorigenicity for MSC-CM PTX than for CTRL and free PTX in TNBC cell lines. Further studies will provide more information about activity and potentially open the possibility of using this new drug delivery vector in the context of a clinical study. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells and Dendritic Cells in Immune Diseases and Cancers)
►▼ Show Figures

Figure 1

15 pages, 2124 KiB  
Article
Tailored PGE2 Immunomodulation of moDCs by Nano-Encapsulated EP2/EP4 Antagonists
by Johanna Bödder, Leanne M. Kok, Jonathan A. Fauerbach, Georgina Flórez-Grau and I. Jolanda M. de Vries
Int. J. Mol. Sci. 2023, 24(2), 1392; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24021392 - 11 Jan 2023
Cited by 2 | Viewed by 2158
Abstract
Prostaglandin E2 (PGE2) is an important maturation mediator for dendritic cells (DCs). However, increased PGE2 levels in the tumor exert immunosuppressive effects on DCs by signaling through two E-Prostanoid (EP) receptors: EP2 and EP4. Blocking EP-receptor signaling of PGE2 with antagonists is currently [...] Read more.
Prostaglandin E2 (PGE2) is an important maturation mediator for dendritic cells (DCs). However, increased PGE2 levels in the tumor exert immunosuppressive effects on DCs by signaling through two E-Prostanoid (EP) receptors: EP2 and EP4. Blocking EP-receptor signaling of PGE2 with antagonists is currently being investigated for clinical applications to enhance anti-tumor immunity. In this study, we investigated a new delivery approach by encapsulating EP2/EP4 antagonists in polymeric nanoparticles. The nanoparticles were characterized for size, antagonist loading, and release. The efficacy of the encapsulated antagonists to block PGE2 signaling was analyzed using monocyte-derived DCs (moDCs). The obtained nanoparticles were sized between 210 and 260 nm. The encapsulation efficacy of the EP2/EP4 antagonists was 20% and 17%, respectively, and was further increased with the co-encapsulation of both antagonists. The treatment of moDCs with co-encapsulation EP2/EP4 antagonists prevented PGE2-induced co-stimulatory marker expression. Even though both antagonists showed a burst release within 15 min at 37 °C, the nanoparticles executed the immunomodulatory effects on moDCs. In summary, we demonstrate the functionality of EP2/EP4 antagonist-loaded nanoparticles to overcome PGE2 modulation of moDCs. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells and Dendritic Cells in Immune Diseases and Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 2219 KiB  
Review
The Immunological Microenvironment and the Emerging Role of Stem Cells Therapy in Peyronie’s Disease: A Systematic Narrative Review
by Che-Hsueh Yang, Dian-Yu Lin, Yi-Sheng Lin, Chao-Yu Hsu, Min-Che Tung, Kok-Tong Tan and Yen-Chuan Ou
Int. J. Mol. Sci. 2023, 24(1), 777; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24010777 - 1 Jan 2023
Cited by 3 | Viewed by 2497
Abstract
Current literature has indicated that Peyronie’s disease (PD) could be initiated by microtrauma and the subsequent inflammation episodes that follow. PD could be sorted into acute or chronic status, and it can differ when selecting the clinical therapeutics. PD would cause pain and [...] Read more.
Current literature has indicated that Peyronie’s disease (PD) could be initiated by microtrauma and the subsequent inflammation episodes that follow. PD could be sorted into acute or chronic status, and it can differ when selecting the clinical therapeutics. PD would cause pain and penile deformity to diseased men and impair their erectile function. Occasionally, surgical revision of the penis might be needed to correct the penile curvature. We find that there are limited effective options of intra-lesion injections for the PD plaques. By searching the databases and screening the literature with the PRISMA 2020 guideline, we observed that several preclinical studies that applied stem cell therapy in treating PD were fruitful in the acute phase. Although in the chronic phase of PD, erectile parameters were not significantly improved, and therefore, future studies might be better elevated in certain aspects, such as the sites selected for harvesting stem cells or changing the centrifugation forces. In this review, we concluded the contemporary understanding of inflammatory microenvironments in PD, the stem cell therapy in PD, and our perspectives on future studies. We concluded that there may be great potential in stem cell therapy for treating both acute and chronic phases PD. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells and Dendritic Cells in Immune Diseases and Cancers)
►▼ Show Figures

Figure 1

13 pages, 1594 KiB  
Review
Regulation of Myeloid Dendritic Cells by Synthetic and Natural Compounds for the Treatment of Rheumatoid Arthritis
by Hira Umbreen, Xiang Zhang, Kuo-Tung Tang and Chi-Chien Lin
Int. J. Mol. Sci. 2023, 24(1), 238; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24010238 - 23 Dec 2022
Cited by 1 | Viewed by 2082
Abstract
Different subsets of dendritic cells (DCs) participate in the development of rheumatoid arthritis (RA). In particular, myeloid DCs play a key role in the generation of autoreactive T and B cells. Herein, we undertook a literature review on those synthetic and natural compounds [...] Read more.
Different subsets of dendritic cells (DCs) participate in the development of rheumatoid arthritis (RA). In particular, myeloid DCs play a key role in the generation of autoreactive T and B cells. Herein, we undertook a literature review on those synthetic and natural compounds that have therapeutic efficacy/potential for RA and act through the regulation of myeloid DCs. Most of these compounds inhibit both the maturation of DCs and their secretion of inflammatory cytokines and, subsequently, alter the downstream T-cell response (suppression of Th1 and Th17 responses while expanding the Treg response). The majority of the synthetic compounds are approved for the treatment of patients with RA, which is consistent with the importance of DCs in the pathogenesis of RA. All of the natural compounds are derived from plants. Their DC-modulating effect has been demonstrated both in vitro and in vivo. In addition, these natural products ameliorate arthritis in rodents and are potential therapeutics for human RA. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells and Dendritic Cells in Immune Diseases and Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop